Modular Medical

Modular Medical, Inc. is a development stage company, which engages in the provision of insulin pump technology. It focuses on the design and commercialization of insulin pumps to serve the diabetes market. The company was founded by Paul M. DiPerna on October 22, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Modular Medical, Inc. is a development stage company, which engages in the provision of insulin pump technology. It focuses on the design, development, and commercialization of insulin pumps to serve the diabetes market. The company was founded by Paul M. DiPerna on October 22, 1998 and is headquartered in San Diego, CA.

Meet with Modular Medical CEO, Jeb Besser Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks Discover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing." The event is scheduled to begin at 8:00am pacific/11:00am eastern on Monday, November 11, 2024.

Registration Is Now Open For Tribe Public's Webinar Event "Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing" Featuring Modular Medical CEO On Monday, November 11, 2024

-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone -Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced successful results from its pre-clinical GLP-1 proof of concept study. "We are excited by the results of this pre-clinical, proof of concept study in a standard obese mouse model," stated Dr. David Maggs, M.D.

Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on October 1, 2024. Company Webcast The Company's webcasted presentation will take place at 2:00 p.m.

Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1

Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 product SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599.

Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology

-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations -CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time SAN DIEGO, CA / ACCESSWIRE / September 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user friendly and affordable design, today announced an update on its proof-of-concept study in a high-fat diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies.

Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform

Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024

SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U.

Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities Commercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States.

Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028 The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032 Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1 Meet with Modular Medical CEO Jeb Besser SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes Care Innovator Modular Medical Takes Next Steps." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, August 9, 2024.

Registration is Now Open for Tribe Public's Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024

SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico. Phillips Medisize, a Molex company, has been an outstanding collaborator in the development of Modular Medical's platform product, supply chain and manufacturing operations, as the Company intends to transition from pre-commercial production to high-volume device manufacturing.

Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / ACCESSWIRE / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a proof-of-concept study with Gubra A/S ("Gubra") in a high-fat, diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. "A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks," commented Jeb Besser, Chief Executive Officer of Modular Medical.

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Modular Medical Announces Addition to the Russell Microcap(R) Index

SAN DIEGO, CA / ACCESSWIRE / March 26, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering. Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D leadership positions with Cytrellis Biosystems, Inc., Onduo, a joint venture between Sanofi SA and Verily Life Sciences, and Insulet Corporation.

Modular Medical Announces Steve Gemmell as New Vice President of Engineering

Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US. 100% of patient population require daily insulin injection.

Registration Is Now Open for Tribe Public's Webinar Event "Revolutionizing Diabetes Care" Featuring Modular Medical CEO on Wednesday, March 6, 2024

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, announced today the closing of its previously announced underwritten public offering (the "offering") of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical's Chief Executive Officer, and Morgan Frank, a member of the Company's board of directors, and other existing institutional investors.

Modular Medical Announces Closing of $10 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that it has priced its underwritten public offering (the "offering") of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical's Chief Executive Officer, and Morgan Frank, a member of the Company's board of directors, and other existing institutional investors.

Modular Medical Announces Pricing of $10 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants).

Modular Medical Announces Proposed Public Offering

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent

Modular Medical, Inc. (MODD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Modular Medical, Inc. (MODD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SAN DIEGO, CA / ACCESSWIRE / January 24, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the issuance of U.S. Patent 11,817,197 B2 for the stream-lined pairing of a pump to a mobile device. Paul DiPerna, Chairman and CTO of Modular Medical, commented, "The issuance of this patent is just another step in our mission to use technology to rethink and simplify the adoption of and ability to live with pump technology for patients and caregivers.

Modular Medical Announces Issuance of New US Patent

SAN DIEGO, CA / ACCESSWIRE / January 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance. "This is an exciting milestone for the Company, as we seek to change the diabetes market.

Modular Medical Announces 510(k) Submission of MODD1 Insulin Pump

SAN DIEGO, CA / ACCESSWIRE / December 21, 2023 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a collaboration agreement with Glooko, Inc., a global leader specializing in connected care and remote patient monitoring for diabetes. Integrating with Glooko will allow clinicians and patients to easily review insulin dosing data from the MODD1 pump, when commercially available.

Modular Medical Announces Collaboration with Glooko

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes Care For The Rest Of Us." Featuring Modular Medical CEO On Friday, December 15, 2023

SAN DIEGO, CA / ACCESSWIRE / November 14, 2023 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced it will be presenting at the Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023 at the New York Athletic Club in New York City. Jeb Besser, CEO, is scheduled to host one-on-one meetings with analysts and investors throughout the day.

Modular Medical to Attend the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, CA / ACCESSWIRE / October 31, 2023 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today provided an update on its ongoing pre-submission testing and timeline for submission of its MODD-1 insulin pump (the "MODD-1") to the U.S. Food and Drug Administration ("FDA"). The Company has made substantial progress on completing many of the tests required for submission and now has results back from some of the longest lead time tests, including insulin stability and potency.

News for Modular Medical Stock (MODD)